Previous 10 | Next 10 |
Otonomy (OTIC): Q3 GAAP EPS of -$0.22 beats by $0.02.Revenue of $0.05M (-61.5% Y/Y) misses by $0.01M.FY2020 guidance: Non-GAAP operating expenses of $35M-$38M , GAAP operating expenses of $45M-$48M. Cash equivalents, and short-term investments will be sufficient to fund the company’s o...
Enrollment completed in Phase 3 clinical trial of OTIVIDEX ® in Ménière’s disease with results expected in the first quarter of 2021 Positive results reported for Phase 1/2 ...
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the third quarter of 2020 and provide a corporate update ...
Bristol Myers Squibb receives FDA approval for immunotherapy combo. iBio inks deal with Safi Biosolutions for harnessing FastPharming System. Otonomy reports completing patient recruitment for Otividex trial. For further details see: Bristol Myers Squibb's Newest Immunot...
Otonomy (OTIC) has completed the enrollment of 142 subjects in a Phase 3 clinical trial evaluating Otividex, a sustained-exposure formulation of the corticosteroid dexamethasone injected through the eardrum, in patients with Ménière’s disease, a disorder of the inner ear...
SAN DIEGO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 3 clinical trial of OTIVIDEX in Méni...
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in four upcoming virtual investor conferences. ...
MICT (NASDAQ: MICT ) +95% on first major order for SmartCam. More news on: MICT, Inc., Forward Industries, Inc., iMedia Brands, Inc., Stocks on the move, , Read more ...
The following slide deck was published by Otonomy, Inc. in conjunction with this Read more ...
For Q2 , Otonomy ( OTIC +4.2% ) product sales of $10K vs. $190K in year ago period; EPS of -$0.37 vs. -$0.38. More news on: Otonomy, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that the company’s shares would be suspended from trading on Nasdaq effective at...
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan of Liquidation and Dissolution (“Plan of Dissolution”) that would include...